Skip to main content

Table 2 Comparison of results (group A and group B).

From: The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

 

Virus Suppression

Therapy success

 

Group A

Median

Viral load

Group B

Median Viral load

Mann-Whitney

Group A

Success

Group B Success

χ2

Baseline

26,950

(N = 10)

8,800

(N = 17)

P = 0.12

0%

(N = 10)

5.9%

(N = 17)

P = 0.998

Week 12

370

(N = 10)

< 50

(N = 15)

P = 0.07

40.0%

(N = 10)

66.7%

(N = 15)

P = 0.035

Week 24

4650

(N = 8)

< 50

(N = 13)

P = 0.16

37.5%

(N = 8)

69.2%

(N = 13)

P = 0.166

Week 48

3410

(N = 7)

< 50

(N = 13)

P = 0.19

42.9%

(N = 7)

53.8%

(N = 13)

P = 0.425

Week 96

15,045

(N = 6)

< 50

(N = 9)

P = 0.044

16.7%

(N = 6)

54.5%

(N = 9)

P = 0.002

  1. Comparison of results (group A and group B). Median viral loads and the therapy success rates illustrate a significantly better long-term suppression of HIV when SQV/ATV plus optimized backbone therapy is combined with a L76V-selecting drug. In bivariate analysis, these results were independent from slightly different baseline viral loads ( < 0,5log) between group A and B.
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us